"Much like the well-known climate threshold of 1.5 degrees Celsius, the importance of critical limits in our environment have long been understood as key to help us avoid calamities. So, when we know the world is facing an escalating antimicrobial resistance (AMR) crisis, but there has been no definitive tipping point established, that leaves us on a potentially perilous path."
"What is antimicrobial resistance and how big a problem is it? These findings add to a growing body of evidence to suggest the most difficult-to-treat infections are beginning to outpace antibiotic development, either because the right antibiotics are not reaching the people who need them, or because they are not being developed in the first place. As a result, the number of AMR deaths is expected to increase sharply, by 70% by 2050."
"Given the amount of focus and funding that is going into encouraging drug companies to invest in research and development, the message we need to take from this is that it is not enough to just develop new antibiotics. They have to be the right antibiotics, those that target infections that have the greatest public health impact. That is not the case."
Data from more than 100 countries show drug-resistant infections have risen significantly, accounting for up to a third of infections in some regions. The most difficult-to-treat infections are beginning to outpace antibiotic development because appropriate antibiotics are not reaching those who need them or are not being developed. AMR deaths are projected to increase by about 70% by 2050. Approximately 90 antimicrobials are in clinical development, but only five innovative candidates target at least one WHO priority pathogen. The current pipeline fails to replace antibiotics lost to resistance, and a severe lack of data compounds the problem.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]